A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. That said, here is one low-volatility stock providing safe-and-steady growth and two stuck in limbo.

Two Stocks to Sell:

Taylor Morrison Home (TMHC)

Rolling One-Year Beta: 0.62

Named “America’s Most Trusted Home Builder” in 2019, Taylor Morrison Home (NYSE: TMHC) builds single family homes and communities across the United States.

Why Is TMHC Not Exciting?

1. Demand cratered as it couldn’t win new orders over the past two years, leading to an average 14.5% decline in its backlog
2. Sales are projected to tank by 14.7% over the next 12 months as demand evaporates
3. Earnings growth underperformed the sector average over the last two years as its EPS grew by just 2.6% annually

At $61.65 per share, Taylor Morrison Home trades at 10x forward P/E. Dive into our free research report to see why there are better opportunities than TMHC.

Gilead Sciences (GILD)

Rolling One-Year Beta: 0.22

From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ: GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.

Why Does GILD Worry Us?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 3.2% over the last two years was below our standards for the healthcare sector
2. Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 7.8 percentage points
3. Waning returns on capital imply its previous profit engines are losing steam

Gilead Sciences is trading at $142.88 per share, or 17.2x forward P/E. If you’re considering GILD for your portfolio, see our FREE research report to learn more.

One Stock to Watch:

Stryker (SYK)

Rolling One-Year Beta: 0.69

With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.

Why Do We Like SYK?

1. Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 10.2% over the past two years
2. Economies of scale give it some operating leverage when demand rises
3. Incremental sales over the last five years have been more profitable as its earnings per share increased by 12.9% annually, topping its revenue gains

Stryker’s stock price of $365.28 implies a valuation ratio of 24.6x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.